Clinical trial · Observational
Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Aldosterone excess can cause oxidative stress leading to DNA damage in vitro and in vivo. Single case reports demonstrated a coincidence of primary aldosteronism (PA) with different malignancies. A higher prevalence of thyroid nodules and non-toxic multinodular goiter was described in patients with PA compared to those with essential hypertension (EH). A single study showed an association between PA and papillary thyroid cancer (PTC), but without a paired control group. Objective: To assess PA prevalence in a transversal cohort of patients with PTC and EH compared to a paired control group with HT.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Primary Aldosteronism | — | UNRESOLVED | — |
| Thyroid Cancer, Papillary | Thyroid Gland Papillary Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Secreening test for primary aldosteronism and Confirmatory Testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients with papillary thyroid cancer (PTC) and EH (essential hypertension)
- description
- Primary Aldosteronism was investigated in all patients with PTC and EH (n= 137), regardless of hypertension severity, under active surveillance at a cancer institute from 2019 to 2022.
- interventionNames
- Diagnostic Test: Secreening test for primary aldosteronism and Confirmatory Testing
- label
- Patients with EH (essential hypertension) previously investigated for PA (primary aldosteronism)
- description
- The control group included 137 (1:1) age,sex and body mass index (BMI) matched individuals from a retrospective cohort of EH previously investigated for PA from 2011 to 2022.
Primary outcomes (1)
- measure
- PA prevalence in a transversal cohort of patients with PTC and EH
- timeFrame
- Through study completion, an average of 1,5 year
- description
- To assess PA prevalence in a transversal cohort of patients with PTC and EH compared to a paired control group with EH
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All patients with PTC and EH regardless of hypertension severity Exclusion Criteria: * Patients who were using medications that secondarily increase blood pressure levels were excluded * Did not agree to participate
References
Publications (0)
Data not yet available